HomeCompareJNJ vs EQT

JNJ vs EQT: Dividend Comparison 2026

JNJ yields 2.14% · EQT yields 1.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQT wins by $4.56M in total portfolio value
10 years
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →
EQT
EQT
● Live price
1.00%
Share price
$64.41
Annual div
$0.65
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.59M
Annual income
$3,847,685.36
Full EQT calculator →

Portfolio growth — JNJ vs EQT

📍 EQT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJNJEQT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JNJ + EQT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JNJ pays
EQT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
EQT
Annual income on $10K today (after 15% tax)
$85.12/yr
After 10yr DRIP, annual income (after tax)
$3,270,532.56/yr
At 15% tax rate, EQT beats the other by $3,266,495.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JNJ + EQT for your $10,000?

JNJ: 50%EQT: 50%
100% EQT50/50100% JNJ
Portfolio after 10yr
$2.31M
Annual income
$1,926,217.62/yr
Blended yield
83.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQT right now

JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
EQT
Analyst Ratings
29
Buy
15
Hold
Consensus: Buy
Price Target
$41.11
-36.2% upside vs current
Range: $23.00 — $55.00
Altman Z
2.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JNJ buys
0
EQT buys
4
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$EQT▲ Buy$1,001 - $15,0002026-02-10
Ro Khanna🏢 House$EQT▲ Buy$15,001 - $50,0002025-10-24
Ritchie Torres🏢 House$EQT▼ Sell$1,001 - $15,0002025-07-11
Rob Bresnahan🏢 House$EQT▲ Buy$1,001 - $15,0002025-04-08
Ritchie Torres🏢 House$EQT▲ Buy$1,001 - $15,0002024-09-26
Bill Hagerty🏛 Senate$EQT▼ Sell$15,001 - $50,0002024-07-22
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJNJEQT
Forward yield2.14%1.00%
Annual dividend / share$5.20$0.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28%100%
Portfolio after 10y$30.5K$4.59M
Annual income after 10y$4,749.88$3,847,685.36
Total dividends collected$15.6K$4.50M
Payment frequencyquarterlyquarterly
SectorHealthcareEnergy
Analyst consensusBuyBuy
Analyst price target$228.73$41.11

Year-by-year: JNJ vs EQT ($10,000, DRIP)

YearJNJ PortfolioJNJ Income/yrEQT PortfolioEQT Income/yrGap
1← crossover$10,594$274.49$10,900$200.28$306.00EQT
2$11,294$360.69$12,071$408.06$777.00EQT
3$12,133$476.91$13,761$844.67$1.6KEQT
4$13,156$635.42$16,524$1,799.81$3.4KEQT
5$14,432$854.61$21,720$4,039.61$7.3KEQT
6$16,056$1,162.76$33,166$9,925.10$17.1KEQT
7$18,175$1,604.53$63,815$28,327.33$45.6KEQT
8$21,009$2,252.68$170,160$101,878.32$149.2KEQT
9$24,911$3,229.73$689,838$507,766.67$664.9KEQT
10$30,458$4,749.88$4,585,812$3,847,685.36$4.56MEQT

JNJ vs EQT: Complete Analysis 2026

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

EQTEnergy

EQT Corporation operates as a natural gas production company in the United States. The company produces natural gas, natural gas liquids (NGLs), including ethane, propane, isobutane, butane, and natural gasoline. As of December 31, 2021, it had 25.0 trillion cubic feet of proved natural gas, NGLs, and crude oil reserves across approximately 2.0 million gross acres, including 1.7 million gross acres in the Marcellus play. The company was founded in 1878 and is headquartered in Pittsburgh, Pennsylvania.

Full EQT Calculator →
📬

Get this JNJ vs EQT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JNJ vs ABBVJNJ vs MRKJNJ vs PFEJNJ vs BMYJNJ vs LLYJNJ vs SCHDJNJ vs JEPIJNJ vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.